Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
The final WUN Town Hall of 2024 took place on November 16th in Cincinnati, Ohio! Attendees...
GivingTuesday is a global generosity movement where donors and nonprofits team up to transform their...
The Syracuse WUN Town Hall took place on November 9th in Baldwinsville, New York! The event...
For the third year in a row, Wake Up Narcolepsy (WUN) is excited to announce...
Wake Up Narcolepsy (WUN), a nonprofit dedicated to driving Narcolepsy awareness, education and research, announced...
Wake Up Narcolepsy (WUN) is looking for your support for our End of Year Giving...
Registration is now open for Wake Up Narcolepsy (WUN)’s 2025 National Summit on April 26th...
Wake Up Narcolepsy (WUN) was pleased to take part in the 2024 Sleep Advocacy Forum! The...
DUBLIN, Oct. 31, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts presenting data...